The Shingles National Immunisation Programme Has Changed

This web page has been
sponsored by GSK

If you could help prevent shingles suffering, why wouldn’t you?

The time to act is now!

This web page has been
sponsored by GSK

Shingles is a painful disease that can have serious and long-lasting complications¹

Prescribing information can be found at the bottom of this page.

Are you aware of the recent changes to the Shingles National Immunisation Programme?

Impact of shingles

Learn more

There are critical steps to ensure your GP surgery is set up to implement the programme

Hear from experts on the changes to the Shingles National Immunisation Programme. Gain access to resources and more with a GSKpro account.

Prescribing information (GB)

OPEN
Prescribing information (NI)

OPEN
Summary of product characteristics (GB)

OPEN
Summary of product characteristics (NI)

OPEN

Adverse events should be reported. Reporting forms and information can be found at
https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.

SHINGRIX is owned by or licensed to the GSK group of companies.
© 2022 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

References

1. UK NICE Clinical Knowledge Summaries (Shingles) August 2021
2. The GreenBook chapter 28a – Shingles. July 2023

PM-GB-SGX-WCNT-230037
September 2023

If you could help prevent shingles suffering, why wouldn’t you?

The time to act is now!

Shingles is a painful disease that can have serious and long-lasting complications1

There are critical steps to ensure your GP surgery is set up to implement the programme

Prescribing information (GB)

Prescribing information (NI)

Summary of product characteristics (GB)

Summary of product characteristics (NI)

Shingles is a painful disease that can have serious and long-lasting complications¹